Stock 2105 LAEKNA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Laekna, Inc.

Equities

2105

KYG5340S1093

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:39 2024-05-28 EDT 		5-day change 1st Jan Change
7.04 HKD +0.14% Intraday chart for Laekna, Inc. -9.16% -64.62%
05-23 US FDA Gives Green Light to Laekna's Phase 3 Trial for Prostate Cancer Drug; Shares Rise 8% MT
05-23 Laekna, Inc. Announces Approval by the U.S. Food and Drug Administrationfor the Phase III Clinical Trial Protocol Of LAE002 (Afuresertib) Plus LAE001 for the Treatment Ofprostate Cancer CI

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
US FDA Gives Green Light to Laekna's Phase 3 Trial for Prostate Cancer Drug; Shares Rise 8%
MT
Laekna, Inc. Announces Approval by the U.S. Food and Drug Administrationfor the Phase III Clinical Trial Protocol Of LAE002 (Afuresertib) Plus LAE001 for the Treatment Ofprostate Cancer
CI
Lekna, Inc. Obtains IND Approval from the CDE for LAE102
CI
Lekna, Inc. Obtains Investigational New Drug Approval from the U.S. Food and Drug Administration for LAE102
CI
Laekna Shrinks Loss in Fiscal 2023
MT
Laekna, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Lekna, Inc. Submits Investigational New Drug Application for LAE102 for the Treatment of Obtains Treatment of Obtains Treatment to the U.S. Food and Drug Administration
CI
Laekna, Inc. Announces the Centre for Drug Evaluation of the National Medical Products Administration of China Accepts the Investigational New Drug Application for Lae102
CI
Laekna, Inc. Announces Top-Line Data of the Global MRCT Phase II Registrational Trial (PROFECTA-II) in Both the U.S. and China
CI
Laekna, Inc. Announces Presentation of the Study Results from Core Product Furesertib at the 2023 SABCS
CI
Laekna Shrinks Loss in H1
MT
Laekna, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Laekna Opens Higher in Hong Kong Trading Debut
MT
Laekna, Inc. has completed an IPO in the amount of HKD 790.86448 million.
CI
Laekna Raises HK$708 Million in Hong Kong IPO
MT
Laekna, Inc. has filed an IPO in the amount of HKD 790.86448 million.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 2105 Stock
  4. News Laekna, Inc.
  5. Highlights